LIGAND PHARMACEUTICALS INCLGND

Market cap
$14.4億
P/E ratio
27.6
2011年
12月31日
2012年
12月31日
2013年
12月31日
2014年
12月31日
2015年
12月31日
2016年
12月31日
2017年
12月31日
2018年
12月31日
2019年
12月31日
2020年
12月31日
2021年
12月31日
2022年
12月31日
2023年
12月31日
Net income (loss)11255-213143629-357-33
Net income (loss)10-11112257-213143629-357-3352
Gain on sale of Pelican172
Change in estimated fair value of contingent liabilities-1-2-4-5-5-3-3-30-13710
Depreciation, Depletion and Amortization333331112151826515237
Loss (gain) short-term investments-17-42946
Amortization/accretion of premium (discount) on investments, net-00510-1-0-01
Amortization of debt discount and issuance fees1011124430231710
Loss (gain) on debt extinguishment-74
Gain on derivative instruments0
Amortization of commercial license and other economic rights252-0-0-1
Loss (gain) on debt extinguishment-74
Lease amortization expense62
Amortization of commercial license and other economic rights252-0-0-1
Share-based compensation34611121925212531396026
Adjustment to credit loss reserves of commercial license rights4
Deferred income taxes, net131-0-0220-11-45-30-75199-21-12
Impairment loss of commercial license rights1
Other0-13201
Lease amortization expense62
Accounts receivable, net4-2-210-69830-252629-553
Inventory-1-1-1-400132180-1211
Accounts payable and accrued liabilities-12-5-3-3-4-2-2-5-7-13-3-5
Other economic rights5
Income taxes receivable and payable11-94-22
Accounts payable and accrued liabilities-12-5-3-3-4-2-2-5-7-13-3-5
Deferred revenue-129-18-60
Income taxes receivable and payable11-94-22
Other assets and liabilities-610
Deferred revenue-129-18-60
Other assets and liabilities-610
Share-based compensation34611121925212531396026
Losses from equity method investment in Primrose Bio-5-23-2423-2
Deferred income taxes, net131-0-0220-11-45-30-75199-21-12
Other0-13201
Accounts receivable, net4-2-210-69830-252629-553
Inventory-1-1-1-400132180-1211
Accounts payable and accrued liabilities-12-5-3-3-4-2-2-5-7-13-3-5
Other economic rights5
Income taxes receivable and payable11-94-22
Accounts payable and accrued liabilities-12-5-3-3-4-2-2-5-7-13-3-5
Deferred revenue-129-18-60
Income taxes receivable and payable11-94-22
Other assets and liabilities-610
Deferred revenue-129-18-60
Other assets and liabilities-610
Net cash provided by operating activities-102121426394194-29557913850
Net income (loss)11255-213143629-357-33
Net income (loss)10-11112257-213143629-357-3352
Gain on sale of Pelican172
Change in estimated fair value of contingent liabilities-1-2-4-5-5-3-3-30-13710
Depreciation, Depletion and Amortization333331112151826515237
Loss (gain) short-term investments-17-42946
Amortization/accretion of premium (discount) on investments, net-00510-1-0-01
Amortization of debt discount and issuance fees1011124430231710
Loss (gain) on debt extinguishment-74
Gain on derivative instruments0
Amortization of commercial license and other economic rights252-0-0-1
Loss (gain) on debt extinguishment-74
Lease amortization expense62
Amortization of commercial license and other economic rights252-0-0-1
Share-based compensation34611121925212531396026
Adjustment to credit loss reserves of commercial license rights4
Deferred income taxes, net131-0-0220-11-45-30-75199-21-12
Impairment loss of commercial license rights1
Other0-13201
Lease amortization expense62
Accounts receivable, net4-2-210-69830-252629-553
Inventory-1-1-1-400132180-1211
Accounts payable and accrued liabilities-12-5-3-3-4-2-2-5-7-13-3-5
Other economic rights5
Income taxes receivable and payable11-94-22
Accounts payable and accrued liabilities-12-5-3-3-4-2-2-5-7-13-3-5
Deferred revenue-129-18-60
Income taxes receivable and payable11-94-22
Other assets and liabilities-610
Deferred revenue-129-18-60
Other assets and liabilities-610
Share-based compensation34611121925212531396026
Losses from equity method investment in Primrose Bio-5-23-2423-2
Deferred income taxes, net131-0-0220-11-45-30-75199-21-12
Other0-13201
Accounts receivable, net4-2-210-69830-252629-553
Inventory-1-1-1-400132180-1211
Accounts payable and accrued liabilities-12-5-3-3-4-2-2-5-7-13-3-5
Other economic rights5
Income taxes receivable and payable11-94-22
Accounts payable and accrued liabilities-12-5-3-3-4-2-2-5-7-13-3-5
Deferred revenue-129-18-60
Income taxes receivable and payable11-94-22
Other assets and liabilities-610
Deferred revenue-129-18-60
Other assets and liabilities-610
Net cash provided by operating activities-102121426394194-29557913850
Cash paid for acquisition, net of cash and restricted cash acquired414932761240510
Purchase of commercial license rights181050
Purchases of property and equipment01000221349184
Purchases of short-term investments101661642541,4342,35742318151127
Proceeds from commercial license rights1000
Proceeds from sale of short-term investments19102162587132536395154210149
Proceeds from maturity of short-term investments571191108931,495644672545
Cash paid for equity method investment15
Proceeds on sale of Vernalis R&D, net22
Cash paid for Novan acquisition, net of restricted cash received414932761240510
Other, net000-05-211
Net cash (used) provided in investing activities-251-5-2-113-143-84-42346723231164-12
Net cash transferred to OmniAb at separation2
Repayment at maturity/repurchase of 2023 Notes102092182722215626177
Payments under finance lease obligations10900
Cash paid for OmniAb transaction costs7
Proceeds from bond hedge settlement44012190
Cash paid for debt issuance costs6171
Proceeds from Stock Options Exercised135965203334322
Proceeds from bond hedge settlement44012190
Taxes paid related to net share settlement of equity awards110441685
Proceeds from Stock Options Exercised135965203334322
Share repurchases06804212345378
Taxes paid related to net share settlement of equity awards110441685
Repurchase of warrants30018
Payments to CVR Holders03212
Net cash used in financing activities304-1613082-8329-485-311-138-276-60
Net increase (decrease) in cash, cash equivalents, and restricted cash99-48-24-2825-22
Interest paid264310
Taxes paid000000010424129
Net cash paid for Novan414932761240510
Accrued inventory purchases112022
Accrued Primrose transaction costs1
Unrealized Gain (Loss) on Investments343-1000-0-0-00
Accrued royalty from commercial license rights0
Accrued fixed asset purchases0022
Accrued commercial license rights purchases0
Accrued debt issuance costs0
Accrued fixed asset purchases0022
Accrued inventory purchases112022
Unrealized Gain (Loss) on Investments343-1000-0-0-00
Cash paid for acquisition, net of cash and restricted cash acquired414932761240510
Purchase of commercial license rights181050
Purchases of property and equipment01000221349184
Purchases of short-term investments101661642541,4342,35742318151127
Proceeds from commercial license rights1000
Proceeds from sale of short-term investments19102162587132536395154210149
Proceeds from maturity of short-term investments571191108931,495644672545
Cash paid for equity method investment15
Proceeds on sale of Vernalis R&D, net22
Cash paid for Novan acquisition, net of restricted cash received414932761240510
Other, net000-05-211
Net cash (used) provided in investing activities-251-5-2-113-143-84-42346723231164-12
Net cash transferred to OmniAb at separation2
Repayment at maturity/repurchase of 2023 Notes102092182722215626177
Payments under finance lease obligations10900
Cash paid for OmniAb transaction costs7
Proceeds from bond hedge settlement44012190
Cash paid for debt issuance costs6171
Proceeds from Stock Options Exercised135965203334322
Proceeds from bond hedge settlement44012190
Taxes paid related to net share settlement of equity awards110441685
Proceeds from Stock Options Exercised135965203334322
Share repurchases06804212345378
Taxes paid related to net share settlement of equity awards110441685
Repurchase of warrants30018
Payments to CVR Holders03212
Net cash used in financing activities304-1613082-8329-485-311-138-276-60
Net increase (decrease) in cash, cash equivalents, and restricted cash99-48-24-2825-22
Interest paid264310
Taxes paid000000010424129
Net cash paid for Novan414932761240510
Accrued inventory purchases112022
Accrued Primrose transaction costs1
Unrealized Gain (Loss) on Investments343-1000-0-0-00
Accrued royalty from commercial license rights0
Accrued fixed asset purchases0022
Accrued commercial license rights purchases0
Accrued debt issuance costs0
Accrued fixed asset purchases0022
Accrued inventory purchases112022
Unrealized Gain (Loss) on Investments343-1000-0-0-00